“We were surprised that the cardiovascular benefit was not significantly different across the baseline level of BMI with patients who were only modestly overweight, achieving the same cardiovascular benefit as those with significant obesity. Furthermore, the cardiovascular benefit was not related to the amount of weight that patients lost while taking semaglutide during the study. This reframes GLP-1 receptor agonists as disease modifying agents rather than as 'weight loss jabs.'”
Deanfield et al. (2026) studied this question.